| Antimicrobial and antibiofilm activity of a novel bacteriophage endolysin (LysSW21) against Methicillin-resistant Staphylococcus aureus |
| Paper ID : 1309-IGA |
| Authors |
|
Sadegh Ranjbari1, Narjes Noori Goodarzi2, Maryam Banar1, Farzad Badmasti3, Mir Saeed Yekaninejad4, Mohammad Reza Pourmand *1 1Department of Pathobiology, School of Public Health, and Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran 2Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran 3Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran 4Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran |
| Abstract |
| The growing threat of antibiotic resistance has become a major global concern, driven by the rapid proliferation of drug-resistant bacterial strains. Endolysins exert potent antibacterial effects by enzymatically degrading key structural components of the bacterial cell wall, making them a compelling candidate for the development of novel antimicrobial agents. This study aims to express and purify the endolysin LysSW21, derived from the Staphylococcus environmental phage vB_SauR_SW21, and evaluate its antibacterial and anti-biofilm activity against the methicillin-resistant Staphylococcus aureus (MRSA) strain. In this study, we performed an in silico analysis of the endolysin LysSW21, followed by cloning, expression, and purification of the mature recombinant protein. The purified protein was then tested for its antibacterial and antibiofilm effects against the target MRSA strain. The LysSW21 exhibited potent antibacterial and anti-biofilm activity against MRSA, with a >5-log reduction in bacterial viability observed within 24 hours at a concentration of 50 μg/mL. Furthermore, the enzyme effectively disrupted the MRSA biofilms in vitro. The thermal stability analysis revealed that LysSW21 remained stable across a broad temperature range, from 4°C to 70°C. Similarly, the pH sensitivity test indicated that the enzyme functions effectively within a range of 4.5 to 10.5. Our findings suggest that recombinant endolysin LysSW21 may be a promising antibacterial and anti-biofilm component against MRSA. Further in vivo studies may establish the role of the LysSW21 as a potential therapeutic candidate for MRSA infections. |
| Keywords |
| Bacteriophage therapy; Methicillin-resistant Staphylococcus aureus; Biofilm; Endolysin; LysSW21; antimicrobial resistance |
| Status: Accepted |
